Immunome Inc [IMNM] stock is trading at $13.92, down -2.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMNM shares have gain 12.44% over the last week, with a monthly amount glided 43.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on September 22, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $26. Previously, Craig Hallum started tracking the stock with Buy rating on September 05, 2025, and set its price target to $26. On April 02, 2025, Lake Street initiated with a Buy rating and assigned a price target of $23 on the stock. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $30 on November 08, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $27 as its price target on May 31, 2024. JP Morgan started tracking with a Overweight rating for this stock on April 30, 2024, and assigned it a price target of $24. In a note dated April 15, 2024, Guggenheim initiated a Buy rating and provided a target price of $35 on this stock.
Immunome Inc [IMNM] stock has fluctuated between $5.15 and $15.12 over the past year. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $13.92 at the most recent close of the market. An investor can expect a potential return of 58.05% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Immunome Inc [NASDAQ:IMNM] reported sales of 12.59M for the trailing twelve months, which represents a growth of 69.84%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.84%, Pretax Profit Margin comes in at -16.87%, and Net Profit Margin reading is -16.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.87 and Total Capital is -0.82. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Immunome Inc’s Current Ratio is 12.13. Further, the Quick Ratio stands at 12.13, while the Cash Ratio is 6.29. Considering the valuation of this stock, the price to sales ratio is 96.24, the price to book ratio is 4.50.
Transactions by insiders
Recent insider trading involved BIENAIME JEAN JACQUES, Director, that happened on Jun 03 ’25 when 5000.0 shares were purchased. Director, BIENAIME JEAN JACQUES completed a deal on Mar 25 ’25 to buy 7800.0 shares. Meanwhile, President and CEO SIEGALL CLAY B bought 0.14 million shares on Mar 26 ’25.
